Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 15/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 10/20 | 1.00 |
| ▸ | PRKCG | P05129 | 10/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 10/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 10/20 | 1.00 |
| ▸ | PRKCB | P05771 | 9/20 | 1.00 |
| ▸ | PRKCA | P17252 | 9/20 | 1.00 |
| ▸ | PRKCH | P24723 | 9/20 | 1.00 |
| ▸ | PRKCI | P41743 | 9/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 9/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 9/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 7/20 | 1.00 |
| ▸ | EGFR | P00533 | 7/20 | 1.00 |
| ▸ | PRKACA | P17612 | 7/20 | 1.00 |
| ▸ | PRKACG | P22612 | 6/20 | 1.00 |
| ▸ | PRKACB | P22694 | 6/20 | 1.00 |
| ▸ | SRC | P12931 | 4/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Staurosporine SCHEMBL13780401 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| Staurosporine SCHEMBL14554228 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| Staurosporine SCHEMBL12430819 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| Staurosporine SCHEMBL13168061 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| Staurosporine SCHEMBL23768489 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| Staurosporine SCHEMBL12245439 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| Staurosporine SCHEMBL23793206 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| SCHEMBL12304513 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| SCHEMBL24393902 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD | |
| Staurosporine SCHEMBL21312855 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCGPRKCZPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021162493-A1 | PROTEIN KINASE DEGRADATION INDUCING COMPOUND, AND USE THEREOF | 보로노이 주식회사 | 2021-08-19 | — | — | WO | disclosed |
| US-20090275547-A1 | METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-11-05 | — | — | US | disclosed |
| US-20090018777-A1 | Systems and Methods for Predicitng Ligand-Protein Binding Interactions | HRNCIAR PETER | 2009-01-15 | — | — | US | disclosed |
| US-20090018777-A1 | Systems and Methods for Predicitng Ligand-Protein Binding Interactions | HRNCIAR PETER | 2009-01-15 | — | — | US | disclosed |
| US-20090006040-A1 | Systems and Methods for Representing Protein Binding Sites and Identifying Molecules with Biological Activity | HRNCIAR PETER | 2009-01-01 | — | — | US | disclosed |
| US-20090006040-A1 | Systems and Methods for Representing Protein Binding Sites and Identifying Molecules with Biological Activity | HRNCIAR PETER | 2009-01-01 | — | — | US | disclosed |
| US-20080319677-A1 | Systems and Methods for Designing Molecules with Affinity for Therapeutic Target Proteins | HRNCIAR PETER | 2008-12-25 | — | — | US | disclosed |
| US-20080319677-A1 | Systems and Methods for Designing Molecules with Affinity for Therapeutic Target Proteins | HRNCIAR PETER | 2008-12-25 | — | — | US | disclosed |
| WO-2008144776-A1 | SYSTEMS AND METHODS FOR DESIGNING MOLECULES WITH AFFINITY FOR THERAPEUTIC TARGET PROTEINS | REVEGEN CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275547-A1 | METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS | PI4KA, PI4KB, PIP4K2B | PRKCQ 472/4885PRKD3 416/4885PRKCG 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.